Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Synaptic vesicles of dopaminergic neurons are small, membrane-bound organelles located in the axon terminals of dopamine-producing neurons. They act as storage reservoirs for dopamine, which is accumulated within vesicles chiefly through VMAT2. Upon arrival of an action potential and subsequent calcium influx, SNARE proteins mediate vesicle fusion with the presynaptic membrane, leading to exocytotic release of dopamine into the synaptic cleft. Dysregulation of vesicular dopamine cycling is linked to the pathophysiology of neurodegenerative and neuropsychiatric diseases such as Parkinson’s disease. Although the vesicle itself is not a direct molecular target for drug development, its constituent proteins, such as VMAT2, are established pharmacological targets[1][2][3][5][7].
Not direct. Mechanisms relevant to vesicle function include: Inhibition of VMAT2 (depletes vesicular dopamine, as with tetrabenazine); Promotion of vesicle release or inhibition of dopamine reuptake (as with amphetamines or cocaine).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Synaptic vesicle of dopaminergic neuron.